Tharimmune, Inc. (THAR) Stock Grade

About Tharimmune, Inc.'s fundamentals

Tharimmune is a small-cap biotechnology company with a market capitalization of $97.1 million that is currently unprofitable, having reported a net loss in its latest annual statement with a net margin of 0.0%. The company generated no year-over-year revenue growth, indicating flat sales performance in its most recent period. As a development-stage biotech firm, traditional valuation metrics like P/E ratio and return on equity are not applicable, and the company does not pay a dividend. Investors should note that profitability metrics and growth are both absent from the company's current financial profile.